15077142	142	Cregan SP	Role of AIF in caspase-dependent and caspase-independent cell death.	Oncogene	2004	123
15723618	142	Pacher P	Role of nitrosative stress and peroxynitrite in the pathogenesis of diabetic complications. Emerging new therapeutical strategies.	Current medicinal chemistry	2005	73
15864271	142	Jagtap P	Poly(ADP-ribose) polymerase and the therapeutic effects of its inhibitors.	Nature reviews. Drug discovery	2005	230
18535182	142	Pacher P	Role of the peroxynitrite-poly(ADP-ribose) polymerase pathway in human disease.	The American journal of pathology	2008	108
23370117	142	Curtin NJ	Therapeutic applications of PARP inhibitors: anticancer therapy and beyond.	Molecular aspects of medicine	2013	79
11937178	183	Dahlöf B	Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol.	Lancet	2002	469
15734615	183	Wachtell K	Angiotensin II receptor blockade reduces new-onset atrial fibrillation and subsequent stroke compared to atenolol: the Losartan Intervention For End Point Reduction in Hypertension (LIFE) study.	Journal of the American College of Cardiology	2005	83
19145003	183	Parving HH	Aliskiren Trial in Type 2 Diabetes Using Cardio-Renal Endpoints (ALTITUDE): rationale and study design.	Nephrology, dialysis, transplantation 	2009	51
21035950	183	Saavedra JM	Blockade of brain angiotensin II AT1 receptors ameliorates stress, anxiety, brain inflammation and ischemia: Therapeutic implications.	Psychoneuroendocrinology	2011	48
21242487	183	Birks EJ	Reversal of severe heart failure with a continuous-flow left ventricular assist device and pharmacological therapy: a prospective study.	Circulation	2011	47
22922412	183	McCurley A	Direct regulation of blood pressure by smooth muscle cell mineralocorticoid receptors.	Nature medicine	2012	73
23643589	183	Youn JY	Oxidative stress in atrial fibrillation: an emerging role of NADPH oxidase.	Journal of molecular and cellular cardiology	2013	36
24776703	183	Jiang F	Angiotensin-converting enzyme 2 and angiotensin 1-7: novel therapeutic targets.	Nature reviews. Cardiology	2014	29
15879332	185	Schrader J	Morbidity and Mortality After Stroke, Eprosartan Compared with Nitrendipine for Secondary Prevention: principal results of a prospective randomized controlled study (MOSES).	Stroke	2005	70
17258668	225	Johnston SC	Validation and refinement of scores to predict very early stroke risk after transient ischaemic attack.	Lancet	2007	138
16629855	335	Walldius G	The apoB/apoA-I ratio: a strong, new risk factor for cardiovascular disease and a target for lipid-lowering therapy--a review of the evidence.	Journal of internal medicine	2006	83
22797450	335	Emerging Risk Factors Collaboration.	Lipid-related markers and cardiovascular disease prediction.	JAMA	2012	60
23965489	335	Boekholdt SM	Levels and changes of HDL cholesterol and apolipoprotein A-I in relation to risk of cardiovascular events among statin-treated patients: a meta-analysis.	Circulation	2013	34
24002795	335	Mora S	High-density lipoprotein cholesterol, size, particle number, and residual vascular risk after potent statin therapy.	Circulation	2013	48
27122601	335	Nordestgaard BG	Fasting is not routinely required for determination of a lipid profile: clinical and laboratory implications including flagging at desirable concentration cut-points-a joint consensus statement from the European Atherosclerosis Society and European Federation of Clinical Chemistry and Laboratory Medicine.	European heart journal	2016	31
27431356	335	O'Donnell MJ	Global and regional effects of potentially modifiable risk factors associated with acute stroke in 32 countries (INTERSTROKE): a case-control study.	Lancet	2016	57
19329177	338	Ridker PM	Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trial.	Lancet	2009	177
22539783	338	Parish S	Lipids and lipoproteins and risk of different vascular events in the MRC/BHF Heart Protection Study.	Circulation	2012	50
23122790	338	Tsimikas S	Oxidation-specific biomarkers, prospective 15-year cardiovascular and stroke outcomes, and net reclassification of cardiovascular events.	Journal of the American College of Cardiology	2012	46
25082583	338	Boekholdt SM	Very low levels of atherogenic lipoproteins and the risk for cardiovascular events: a meta-analysis of statin trials.	Journal of the American College of Cardiology	2014	47
7646655	348	Petersen RC	Apolipoprotein E status as a predictor of the development of Alzheimer's disease in memory-impaired individuals.	JAMA	1995	127
8709781	348	Tang MX	Effect of oestrogen during menopause on risk and age at onset of Alzheimer's disease.	Lancet	1996	156
11851541	348	Wilson RS	Participation in cognitively stimulating activities and risk of incident Alzheimer disease.	JAMA	2002	243
12076218	348	Engelhart MJ	Dietary intake of antioxidants and risk of Alzheimer disease.	JAMA	2002	152
12196314	348	Lindsay J	Risk factors for Alzheimer's disease: a prospective analysis from the Canadian Study of Health and Aging.	American journal of epidemiology	2002	197
12499482	348	Wilson RS	Cognitive activity and incident AD in a population-based sample of older persons.	Neurology	2002	103
12558712	348	Haan MN	Prevalence of dementia in older latinos: the influence of type 2 diabetes mellitus, stroke and genetic factors.	Journal of the American Geriatrics Society	2003	110
14728627	348	Fitzpatrick AL	Incidence and prevalence of dementia in the Cardiovascular Health Study.	Journal of the American Geriatrics Society	2004	111
15911795	348	Enzinger C	Risk factors for progression of brain atrophy in aging: six-year follow-up of normal subjects.	Neurology	2005	82
16108925	348	Newman AB	Dementia and Alzheimer's disease incidence in relationship to cardiovascular disease in the Cardiovascular Health Study cohort.	Journal of the American Geriatrics Society	2005	89
17030648	348	Scarmeas N	Mediterranean diet, Alzheimer disease, and vascular mediation.	Archives of neurology	2006	83
17353383	348	Luchsinger JA	Measures of adiposity and dementia risk in elderly persons.	Archives of neurology	2007	62
17420320	348	Luchsinger JA	Relation of diabetes to mild cognitive impairment.	Archives of neurology	2007	135
18663180	348	Cramer C	Use of statins and incidence of dementia and cognitive impairment without dementia in a cohort study.	Neurology	2008	60
19255410	348	Berlau DJ	APOE epsilon2 is associated with intact cognition but increased Alzheimer pathology in the oldest old.	Neurology	2009	59
19273753	348	Helzner EP	Contribution of vascular risk factors to the progression in Alzheimer disease.	Archives of neurology	2009	75
19319544	348	Bell RD	Neurovascular mechanisms and blood-brain barrier disorder in Alzheimer's disease.	Acta neuropathologica	2009	208
19362884	348	Knopman DS	Fourteen-year longitudinal study of vascular risk factors, APOE genotype, and cognition: the ARIC MRI Study.	Alzheimer's and dementia 	2009	72
19671905	348	Féart C	Adherence to a Mediterranean diet, cognitive decline, and risk of dementia.	JAMA	2009	114
20864661	348	Zhu YC	Severity of dilated Virchow-Robin spaces is associated with age, blood pressure, and MRI markers of small vessel disease: a population-based study.	Stroke	2010	58
20876479	348	Poels MM	Prevalence and risk factors of cerebral microbleeds: an update of the Rotterdam scan study.	Stroke	2010	89
21307170	348	Poels MM	Incidence of cerebral microbleeds in the general population: the Rotterdam Scan Study.	Stroke	2011	47
22670023	348	Lal C	Neurocognitive impairment in obstructive sleep apnea.	Chest	2012	53
23424091	348	Gurol ME	Cerebral amyloid angiopathy burden associated with leukoaraiosis: a positron emission tomography/magnetic resonance imaging study.	Annals of neurology	2013	41
23601373	348	Bangen KJ	APOE genotype modifies the relationship between midlife vascular risk factors and later cognitive decline.	Journal of stroke and cerebrovascular diseases 	2013	30
24378418	348	Reed B	Associations between serum cholesterol levels and cerebral amyloidosis.	JAMA neurology	2014	37
24713533	348	Romero JR	Risk factors, stroke prevention treatments, and prevalence of cerebral microbleeds in the Framingham Heart Study.	Stroke	2014	37
24818585	348	Kester MI	Associations between cerebral small-vessel disease and Alzheimer disease pathology as measured by cerebrospinal fluid biomarkers.	JAMA neurology	2014	30
24910016	348	Bu XL	A study on the association between infectious burden and Alzheimer's disease.	European journal of neurology	2015	21
25672924	348	Wang R	Effects of vascular risk factors and APOE ε4 on white matter integrity and cognitive decline.	Neurology	2015	20
26863354	348	Satizabal CL	Incidence of Dementia over Three Decades in the Framingham Heart Study.	The New England journal of medicine	2016	95
27979356	348	Irwin DJ	Neuropathological and genetic correlates of survival and dementia onset in synucleinopathies: a retrospective analysis.	The Lancet. Neurology	2017	30
10833057	351	Roof RL	Gender differences in acute CNS trauma and stroke: neuroprotective effects of estrogen and progesterone.	Journal of neurotrauma	2000	117
22116809	351	Hartz AM	Amyloid-β contributes to blood-brain barrier leakage in transgenic human amyloid precursor protein mice and in humans with cerebral amyloid angiopathy.	Stroke	2012	41
15687315	590	Sink KM	Pharmacological treatment of neuropsychiatric symptoms of dementia: a review of the evidence.	JAMA	2005	119
18063409	590	Chen R	The clinical diagnostic utility of transcranial magnetic stimulation: report of an IFCN committee.	Clinical neurophysiology 	2008	67
15741046	627	Mattson MP	Beneficial effects of intermittent fasting and caloric restriction on the cardiovascular and cerebrovascular systems.	The Journal of nutritional biochemistry	2005	104
18845611	627	Cheeran B	A common polymorphism in the brain-derived neurotrophic factor gene (BDNF) modulates human cortical plasticity and the response to rTMS.	The Journal of physiology	2008	163
20705090	627	Chiu CT	Molecular actions and therapeutic potential of lithium in preclinical and clinical studies of CNS disorders.	Pharmacology and therapeutics	2010	61
20726844	627	Johansson BB	Current trends in stroke rehabilitation. A review with focus on brain plasticity.	Acta neurologica Scandinavica	2011	38
9989963	717	de Lorgeril M	Mediterranean diet, traditional risk factors, and the rate of cardiovascular complications after myocardial infarction: final report of the Lyon Diet Heart Study.	Circulation	1999	271
21486813	717	Sato K	The distribution of blood flow in the carotid and vertebral arteries during dynamic exercise in humans.	The Journal of physiology	2011	44
18585836	966	Kurella Tamura M	Kidney function and cognitive impairment in US adults: the Reasons for Geographic and Racial Differences in Stroke (REGARDS) Study.	American journal of kidney diseases 	2008	105
19218538	966	Schiffmann R	Fabry disease: progression of nephropathy, and prevalence of cardiac and cerebrovascular events before enzyme replacement therapy.	Nephrology, dialysis, transplantation 	2009	68
20884698	966	Di Angelantonio E	Chronic kidney disease and risk of major cardiovascular disease and non-vascular mortality: prospective population based cohort study.	BMJ	2010	48
21737017	966	Haykowsky MJ	Determinants of exercise intolerance in elderly heart failure patients with preserved ejection fraction.	Journal of the American College of Cardiology	2011	76
23489677	966	Dobre M	Association of serum bicarbonate with risk of renal and cardiovascular outcomes in CKD: a report from the Chronic Renal Insufficiency Cohort (CRIC) study.	American journal of kidney diseases 	2013	40
24092942	966	Blood Pressure Lowering Treatment Trialists' Collaboration.	Blood pressure lowering and major cardiovascular events in people with and without chronic kidney disease: meta-analysis of randomised controlled trials.	BMJ	2013	39
24902920	966	Ambrosius WT	The design and rationale of a multicenter clinical trial comparing two strategies for control of systolic blood pressure: the Systolic Blood Pressure Intervention Trial (SPRINT).	Clinical trials	2014	64
25393378	966	Naik RP	Association of sickle cell trait with chronic kidney disease and albuminuria in African Americans.	JAMA	2014	34
25552421	966	Udell JA	Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes and moderate or severe renal impairment: observations from the SAVOR-TIMI 53 Trial.	Diabetes care	2015	22
26038534	966	Molnar MZ	Association of incident obstructive sleep apnoea with outcomes in a large cohort of US veterans.	Thorax	2015	25
17984165	1071	Barter PJ	Effects of torcetrapib in patients at high risk for coronary events.	The New England journal of medicine	2007	539
23126252	1071	Schwartz GG	Effects of dalcetrapib in patients with a recent acute coronary syndrome.	The New England journal of medicine	2012	334
25038074	1071	Keene D	Effect on cardiovascular risk of high density lipoprotein targeted drug treatments niacin, fibrates, and CETP inhibitors: meta-analysis of randomised controlled trials including 117,411 patients.	BMJ	2014	47
16598045	1282	Gould DB	Role of COL4A1 in small-vessel disease and hemorrhagic stroke.	The New England journal of medicine	2006	104
22209247	1282	Jeanne M	COL4A2 mutations impair COL4A1 and COL4A2 secretion and cause hemorrhagic stroke.	American journal of human genetics	2012	37
22914737	1282	Kuo DS	COL4A1 and COL4A2 mutations and disease: insights into pathogenic mechanisms and potential therapeutic targets.	Human molecular genetics	2012	45
3594774	1351	White HD	Left ventricular end-systolic volume as the major determinant of survival after recovery from myocardial infarction.	Circulation	1987	237
11723017	1351	Heitzer T	Endothelial dysfunction, oxidative stress, and risk of cardiovascular events in patients with coronary artery disease.	Circulation	2001	280
14688693	1351	Prasad SM	The Cox maze III procedure for atrial fibrillation: long-term efficacy in patients undergoing lone versus concomitant procedures.	The Journal of thoracic and cardiovascular surgery	2003	92
14769624	1351	Wassertheil-Smoller S	Depression and cardiovascular sequelae in postmenopausal women. The Women's Health Initiative (WHI).	Archives of internal medicine	2004	106
15547162	1351	Devereux RB	Prognostic significance of left ventricular mass change during treatment of hypertension.	JAMA	2004	112
17928595	1351	Ford I	Long-term follow-up of the West of Scotland Coronary Prevention Study.	The New England journal of medicine	2007	83
18378618	1351	Schramm TK	Diabetes patients requiring glucose-lowering therapy and nondiabetics with a prior myocardial infarction carry the same cardiovascular risk: a population study of 3.3 million people.	Circulation	2008	83
19221219	1351	Fung TT	Mediterranean diet and incidence of and mortality from coronary heart disease and stroke in women.	Circulation	2009	145
26384521	1351	Kovesdy CP	Association of Race With Mortality and Cardiovascular Events in a Large Cohort of US Veterans.	Circulation	2015	40
27074389	1351	Twig G	Body-Mass Index in 2.3 Million Adolescents and Cardiovascular Death in Adulthood.	The New England journal of medicine	2016	51
9077376	1401	Ridker PM	Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men.	The New England journal of medicine	1997	570
9490235	1401	Ridker PM	Plasma concentration of C-reactive protein and risk of developing peripheral vascular disease.	Circulation	1998	113
9727541	1401	Ridker PM	Prospective study of C-reactive protein and the risk of future cardiovascular events among apparently healthy women.	Circulation	1998	200
10733371	1401	Ridker PM	C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women.	The New England journal of medicine	2000	841
10807470	1401	Gottdiener JS	Predictors of congestive heart failure in the elderly: the Cardiovascular Health Study.	Journal of the American College of Cardiology	2000	208
11282915	1401	Ridker PM	High-sensitivity C-reactive protein: potential adjunct for global risk assessment in the primary prevention of cardiovascular disease.	Circulation	2001	153
11577954	1401	Noack B	Periodontal infections contribute to elevated systemic C-reactive protein level.	Journal of periodontology	2001	99
11692019	1401	Rost NS	Plasma concentration of C-reactive protein and risk of ischemic stroke and transient ischemic attack: the Framingham study.	Stroke	2001	112
11739301	1401	Chung MK	C-reactive protein elevation in patients with atrial arrhythmias: inflammatory mechanisms and persistence of atrial fibrillation.	Circulation	2001	209
12366601	1401	Blake GJ	Inflammatory bio-markers and cardiovascular risk prediction.	Journal of internal medicine	2002	100
12432042	1401	Ridker PM	Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events.	The New England journal of medicine	2002	521
12551861	1401	Ridker PM	C-reactive protein, the metabolic syndrome, and risk of incident cardiovascular events: an 8-year follow-up of 14 719 initially healthy American women.	Circulation	2003	325
12576356	1401	Enright PL	The 6-min walk test: a quick measure of functional status in elderly adults.	Chest	2003	121
12943870	1401	Cesari M	Inflammatory markers and cardiovascular disease (The Health, Aging and Body Composition Health ABC Study).	The American journal of cardiology	2003	86
14568895	1401	Cesari M	Inflammatory markers and onset of cardiovascular events: results from the Health ABC study.	Circulation	2003	190
14725719	1401	Smith CJ	Peak plasma interleukin-6 and other peripheral markers of inflammation in the first week of ischaemic stroke correlate with brain infarct volume, stroke severity and long-term outcome.	BMC neurology	2004	91
15031312	1401	Tilvis RS	Predictors of cognitive decline and mortality of aged people over a 10-year period.	The journals of gerontology. Series A, Biological sciences and medical sciences	2004	100
15051634	1401	Ridker PM	Clinical usefulness of very high and very low levels of C-reactive protein across the full range of Framingham Risk Scores.	Circulation	2004	74
15197153	1401	Ridker PM	Should C-reactive protein be added to metabolic syndrome and to assessment of global cardiovascular risk?	Circulation	2004	85
15699278	1401	Desvarieux M	Periodontal microbiota and carotid intima-media thickness: the Oral Infections and Vascular Disease Epidemiology Study (INVEST).	Circulation	2005	118
15817606	1401	Wannamethee SG	Associations between cigarette smoking, pipe/cigar smoking, and smoking cessation, and haemostatic and inflammatory markers for cardiovascular disease.	European heart journal	2005	75
16170078	1401	Emsley HC	A randomised phase II study of interleukin-1 receptor antagonist in acute stroke patients.	Journal of neurology, neurosurgery, and psychiatry	2005	117
16219884	1401	Fibrinogen Studies Collaboration.	Plasma fibrinogen level and the risk of major cardiovascular diseases and nonvascular mortality: an individual participant meta-analysis.	JAMA	2005	223
16642000	1401	Pepys MB	Targeting C-reactive protein for the treatment of cardiovascular disease.	Nature	2006	131
16738034	1401	Man SF	C-reactive protein and mortality in mild to moderate chronic obstructive pulmonary disease.	Thorax	2006	86
17043079	1401	Fitzpatrick AL	Leukocyte telomere length and cardiovascular disease in the cardiovascular health study.	American journal of epidemiology	2007	225
17164456	1401	Lange LA	Association of polymorphisms in the CRP gene with circulating C-reactive protein levels and cardiovascular events.	JAMA	2006	69
17389308	1401	Jefferson AL	Inflammatory biomarkers are associated with total brain volume: the Framingham Heart Study.	Neurology	2007	74
17541022	1401	Kiechl S	Oxidized phospholipids, lipoprotein(a), lipoprotein-associated phospholipase A2 activity, and 10-year cardiovascular outcomes: prospective results from the Bruneck study.	Arteriosclerosis, thrombosis, and vascular biology	2007	67
17556718	1401	Drager LF	Effects of continuous positive airway pressure on early signs of atherosclerosis in obstructive sleep apnea.	American journal of respiratory and critical care medicine	2007	102
17576871	1401	Cao JJ	Association of carotid artery intima-media thickness, plaques, and C-reactive protein with future cardiovascular disease and all-cause mortality: the Cardiovascular Health Study.	Circulation	2007	71
17679132	1401	Pradhan AD	Hemoglobin A1c predicts diabetes but not cardiovascular disease in nondiabetic women.	The American journal of medicine	2007	57
17967770	1401	Mora S	Physical activity and reduced risk of cardiovascular events: potential mediating mechanisms.	Circulation	2007	154
17984166	1401	Kjekshus J	Rosuvastatin in older patients with systolic heart failure.	The New England journal of medicine	2007	158
18240558	1401	Ridker PM	Inflammatory biomarkers and risks of myocardial infarction, stroke, diabetes, and total mortality: implications for longevity.	Nutrition reviews	2007	62
18413553	1401	Fung TT	Adherence to a DASH-style diet and risk of coronary heart disease and stroke in women.	Archives of internal medicine	2008	201
18439548	1401	Ridker PM	Loci related to metabolic-syndrome pathways including LEPR,HNF1A, IL6R, and GCKR associate with plasma C-reactive protein: the Women's Genome Health Study.	American journal of human genetics	2008	116
18997196	1401	Ridker PM	Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein.	The New England journal of medicine	2008	1021
19449008	1401	Packard RR	Innate and adaptive immunity in atherosclerosis.	Seminars in immunopathology	2009	49
19567439	1401	Melander O	Novel and conventional biomarkers for prediction of incident cardiovascular events in the community.	JAMA	2009	119
19630828	1401	Ridker PM	Testing the inflammatory hypothesis of atherothrombosis: scientific rationale for the cardiovascular inflammation reduction trial (CIRT).	Journal of thrombosis and haemostasis 	2009	75
19901973	1401	Whiteley W	Inflammatory markers and poor outcome after stroke: a prospective cohort study and systematic review of interleukin-6.	PLoS medicine	2009	51
20031199	1401	Emerging Risk Factors Collaboration.	C-reactive protein concentration and risk of coronary heart disease, stroke, and mortality: an individual participant meta-analysis.	Lancet	2010	412
20176986	1401	Mora S	Statins for the primary prevention of cardiovascular events in women with elevated high-sensitivity C-reactive protein or dyslipidemia: results from the Justification for the Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin (JUPITER) and meta-analysis of women from primary prevention trials.	Circulation	2010	47
20497981	1401	Blankenberg S	Contribution of 30 biomarkers to 10-year cardiovascular risk estimation in 2 population cohorts: the MONICA, risk, genetics, archiving, and monograph (MORGAM) biomarker project.	Circulation	2010	65
21200002	1401	Anderson TJ	Microvascular function predicts cardiovascular events in primary prevention: long-term results from the Firefighters and Their Endothelium (FATE) study.	Circulation	2011	59
21680719	1401	Tan ZS	Association of metabolic dysregulation with volumetric brain magnetic resonance imaging and cognitive markers of subclinical brain aging in middle-aged adults: the Framingham Offspring Study.	Diabetes care	2011	46
21982649	1401	Ridker PM	Interleukin-1β inhibition and the prevention of recurrent cardiovascular events: rationale and design of the Canakinumab Anti-inflammatory Thrombosis Outcomes Study (CANTOS).	American heart journal	2011	187
22357713	1401	Satizabal CL	Circulating IL-6 and CRP are associated with MRI findings in the elderly: the 3C-Dijon Study.	Neurology	2012	56
22414775	1401	Landi F	Sarcopenia as a risk factor for falls in elderly individuals: results from the ilSIRENTE study.	Clinical nutrition	2012	85
22910756	1401	Yeboah J	Comparison of novel risk markers for improvement in cardiovascular risk assessment in intermediate-risk individuals.	JAMA	2012	169
24970784	1401	Dregan A	Chronic inflammatory disorders and risk of type 2 diabetes mellitus, coronary heart disease, and stroke: a population-based cohort study.	Circulation	2014	33
25341516	1401	Guarner V	Low-grade systemic inflammation connects aging, metabolic syndrome and cardiovascular disease.	Interdisciplinary topics in gerontology	2015	33
25632086	1401	Shoamanesh A	Inflammatory biomarkers, cerebral microbleeds, and small vessel disease: Framingham Heart Study.	Neurology	2015	30
27040132	1401	Yusuf S	Cholesterol Lowering in Intermediate-Risk Persons without Cardiovascular Disease.	The New England journal of medicine	2016	54
18332343	1437	Nagel MA	The varicella zoster virus vasculopathies: clinical, CSF, imaging, and virologic features.	Neurology	2008	82
23963331	1440	Ringelstein EB	Granulocyte colony-stimulating factor in patients with acute ischemic stroke: results of the AX200 for Ischemic Stroke trial.	Stroke	2013	30
15901858	1471	Shlipak MG	Cystatin C and the risk of death and cardiovascular events among elderly persons.	The New England journal of medicine	2005	312
16908914	1471	Shlipak MG	Cystatin C and prognosis for cardiovascular and kidney outcomes in elderly persons without chronic kidney disease.	Annals of internal medicine	2006	147
17190862	1471	Ix JH	Association of cystatin C with mortality, cardiovascular events, and incident heart failure among persons with coronary heart disease: data from the Heart and Soul Study.	Circulation	2007	75
21482744	1471	Peralta CA	Detection of chronic kidney disease with creatinine, cystatin C, and urine albumin-to-creatinine ratio and association with progression to end-stage renal disease and mortality.	JAMA	2011	102
23470495	1471	Brouwers FP	Incidence and epidemiology of new onset heart failure with preserved vs. reduced ejection fraction in a community-based cohort: 11-year follow-up of PREVEND.	European heart journal	2013	66
19106083	1557	Simon T	Genetic determinants of response to clopidogrel and cardiovascular events.	The New England journal of medicine	2009	256
19106084	1557	Mega JL	Cytochrome p-450 polymorphisms and response to clopidogrel.	The New England journal of medicine	2009	318
20801494	1557	Mega JL	Genetic variants in ABCB1 and CYP2C19 and cardiovascular outcomes after treatment with clopidogrel and prasugrel in the TRITON-TIMI 38 trial: a pharmacogenetic analysis.	Lancet	2010	80
20801498	1557	Wallentin L	Effect of CYP2C19 and ABCB1 single nucleotide polymorphisms on outcomes of treatment with ticagrelor versus clopidogrel for acute coronary syndromes: a genetic substudy of the PLATO trial.	Lancet	2010	95
20978260	1557	Mega JL	Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis.	JAMA	2010	167
19300499	1559	Takeuchi F	A genome-wide association study confirms VKORC1, CYP2C9, and CYP4F2 as principal genetic determinants of warfarin dose.	PLoS genetics	2009	193
7500533	1628	Launer LJ	The association between midlife blood pressure levels and late-life cognitive function. The Honolulu-Asia Aging Study.	JAMA	1995	134
8439223	1628	Stamler J	Blood pressure, systolic and diastolic, and cardiovascular risks. US population data.	Archives of internal medicine	1993	146
22088239	1628	Liu LS	2010 Chinese guidelines for the management of hypertension.	Zhonghua xin xue guan bing za zhi	2011	122
1463530	1636	SOLVD Investigators.	Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions.	The New England journal of medicine	1992	249
10030325	1636	Hansson L	Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial.	Lancet	1999	130
10675071	1636	-	Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators.	Lancet	2000	341
10716457	1636	Cohn JN	Cardiac remodeling--concepts and clinical implications: a consensus paper from an international forum on cardiac remodeling. Behalf of an International Forum on Cardiac Remodeling.	Journal of the American College of Cardiology	2000	340
11130523	1636	Neal B	Effects of ACE inhibitors, calcium antagonists, and other blood-pressure-lowering drugs: results of prospectively designed overviews of randomised trials. Blood Pressure Lowering Treatment Trialists' Collaboration.	Lancet	2000	198
11759645	1636	Cohn JN	A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure.	The New England journal of medicine	2001	265
12020339	1636	Beckman JA	Diabetes and atherosclerosis: epidemiology, pathophysiology, and management.	JAMA	2002	376
12759325	1636	Psaty BM	Health outcomes associated with various antihypertensive therapies used as first-line agents: a network meta-analysis.	JAMA	2003	150
12829555	1636	Law MR	Value of low dose combination treatment with blood pressure lowering drugs: analysis of 354 randomised trials.	BMJ	2003	185
14769700	1636	McAlister FA	Renal insufficiency and heart failure: prognostic and therapeutic implications from a prospective cohort study.	Circulation	2004	99
15152060	1636	Kadish A	Prophylactic defibrillator implantation in patients with nonischemic dilated cardiomyopathy.	The New England journal of medicine	2004	166
17765963	1636	Patel A	Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial.	Lancet	2007	272
18378520	1636	ONTARGET Investigators.	Telmisartan, ramipril, or both in patients at high risk for vascular events.	The New England journal of medicine	2008	454
18440425	1636	Xavier D	Treatment and outcomes of acute coronary syndromes in India (CREATE): a prospective analysis of registry data.	Lancet	2008	123
18757085	1636	Telmisartan Randomised AssessmeNt Study in ACE iNtolerant subjects with cardiovascular Disease (TRANSCEND) Investigators.	Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomised controlled trial.	Lancet	2008	146
19052124	1636	Jamerson K	Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients.	The New England journal of medicine	2008	250
19706421	1636	Platten M	Blocking angiotensin-converting enzyme induces potent regulatory T cells and modulates TH1- and TH17-mediated autoimmunity.	Proceedings of the National Academy of Sciences of the United States of America	2009	85
20625111	1636	Hsu DT	Enalapril in infants with single ventricle: results of a multicenter randomized trial.	Circulation	2010	53
21544514	1636	Tseng CH	Diabetes and risk of bladder cancer: a study using the National Health Insurance database in Taiwan.	Diabetologia	2011	38
21872920	1636	Yusuf S	Use of secondary prevention drugs for cardiovascular disease in the community in high-income, middle-income, and low-income countries (the PURE Study): a prospective epidemiological survey.	Lancet	2011	147
25203083	1636	Yawn BP	Management of sickle cell disease: summary of the 2014 evidence-based report by expert panel members.	JAMA	2014	156
25300735	1636	Gilbert LK	Childhood adversity and adult chronic disease: an update from ten states and the District of Columbia, 2010.	American journal of preventive medicine	2015	29
22234149	1803	Johansen OE	Cardiovascular safety with linagliptin in patients with type 2 diabetes mellitus: a pre-specified, prospective, and adjudicated meta-analysis of a phase 3 programme.	Cardiovascular diabetology	2012	54
22925682	1803	Monami M	Dipeptidyl peptidase-4 inhibitors and cardiovascular risk: a meta-analysis of randomized clinical trials.	Diabetes, obesity and metabolism	2013	52
23992601	1803	Scirica BM	Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus.	The New England journal of medicine	2013	471
23992602	1803	White WB	Alogliptin after acute coronary syndrome in patients with type 2 diabetes.	The New England journal of medicine	2013	365
24750644	1803	Wu S	Dipeptidyl peptidase-4 inhibitors and cardiovascular outcomes: meta-analysis of randomized clinical trials with 55,141 participants.	Cardiovascular therapeutics	2014	30
25528528	1803	Savarese G	Cardiovascular effects of dipeptidyl peptidase-4 inhibitors in diabetic patients: A meta-analysis.	International journal of cardiology	2015	21
25765696	1803	Zannad F	Heart failure and mortality outcomes in patients with type 2 diabetes taking alogliptin versus placebo in EXAMINE: a multicentre, randomised, double-blind trial.	Lancet	2015	87
26052984	1803	Green JB	Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes.	The New England journal of medicine	2015	260
26063450	1803	Ferrannini E	Impact of glucose-lowering drugs on cardiovascular disease in type 2 diabetes.	European heart journal	2015	33
26457538	1803	Ou SM	Effects on Clinical Outcomes of Adding Dipeptidyl Peptidase-4 Inhibitors Versus Sulfonylureas to Metformin Therapy in Patients With Type 2 Diabetes Mellitus.	Annals of internal medicine	2015	19
27434443	1803	Palmer SC	Comparison of Clinical Outcomes and Adverse Events Associated With Glucose-Lowering Drugs in Patients With Type 2 Diabetes: A Meta-analysis.	JAMA	2016	37
18261470	1906	Wood KC	Sickle cell disease vasculopathy: a state of nitric oxide resistance.	Free radical biology and medicine	2008	57
18698331	1906	Hainsworth AH	Do in vivo experimental models reflect human cerebral small vessel disease? A systematic review.	Journal of cerebral blood flow and metabolism 	2008	65
18829137	1906	Selvamani A	Reproductive age modulates the impact of focal ischemia on the forebrain as well as the effects of estrogen treatment in female rats.	Neurobiology of aging	2010	50
21683931	1906	D'haeseleer M	Vascular aspects of multiple sclerosis.	The Lancet. Neurology	2011	41
20189275	1956	Matsushita K	Risk implications of the new CKD Epidemiology Collaboration (CKD-EPI) equation compared with the MDRD Study equation for estimated GFR: the Atherosclerosis Risk in Communities (ARIC) Study.	American journal of kidney diseases 	2010	67
21189092	1956	de Boer RA	Predictive value of plasma galectin-3 levels in heart failure with reduced and preserved ejection fraction.	Annals of medicine	2011	89
12435860	2056	Ehrenreich H	Erythropoietin therapy for acute stroke is both safe and beneficial.	Molecular medicine	2002	167
12975460	2056	Villa P	Erythropoietin selectively attenuates cytokine production and inflammation in cerebral ischemia by targeting neuronal apoptosis.	The Journal of experimental medicine	2003	109
15178821	2056	Wang L	Treatment of stroke with erythropoietin enhances neurogenesis and angiogenesis and improves neurological function in rats.	Stroke	2004	206
15247477	2056	Leist M	Derivatives of erythropoietin that are tissue protective but not erythropoietic.	Science	2004	167
15928718	2056	Brines M	Emerging biological roles for erythropoietin in the nervous system.	Nature reviews. Neuroscience	2005	105
16634041	2056	Carmichael ST	Cellular and molecular mechanisms of neural repair after stroke: making waves.	Annals of neurology	2006	153
17108343	2056	Singh AK	Correction of anemia with epoetin alfa in chronic kidney disease.	The New England journal of medicine	2006	417
18279854	2056	Theus MH	In vitro hypoxic preconditioning of embryonic stem cells as a strategy of promoting cell survival and functional benefits after transplantation into the ischemic rat brain.	Experimental neurology	2008	63
19834012	2056	Ehrenreich H	Recombinant human erythropoietin in the treatment of acute ischemic stroke.	Stroke	2009	156
21558517	2056	Najjar SS	Intravenous erythropoietin in patients with ST-segment elevation myocardial infarction: REVEAL: a randomized controlled trial.	JAMA	2011	58
16495393	2064	Joensuu H	Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer.	The New England journal of medicine	2006	240
20124182	2064	Baselga J	Phase II trial of pertuzumab and trastuzumab in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer that progressed during prior trastuzumab therapy.	Journal of clinical oncology 	2010	140
20124187	2064	Blackwell KL	Randomized study of Lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer.	Journal of clinical oncology 	2010	194
21991949	2064	Slamon D	Adjuvant trastuzumab in HER2-positive breast cancer.	The New England journal of medicine	2011	410
22513938	2064	Moja L	Trastuzumab containing regimens for early breast cancer.	The Cochrane database of systematic reviews	2012	91
22744937	2064	Sawaya H	Assessment of echocardiography and biomarkers for the extended prediction of cardiotoxicity in patients treated with anthracyclines, taxanes, and trastuzumab.	Circulation. Cardiovascular imaging	2012	75
23475636	2064	Swain SM	Cardiac tolerability of pertuzumab plus trastuzumab plus docetaxel in patients with HER2-positive metastatic breast cancer in CLEOPATRA: a randomized, double-blind, placebo-controlled phase III study.	The oncologist	2013	35
23704196	2064	Schneeweiss A	Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase II cardiac safety study (TRYPHAENA).	Annals of oncology 	2013	100
24239210	2064	Buzdar AU	Fluorouracil, epirubicin, and cyclophosphamide (FEC-75) followed by paclitaxel plus trastuzumab versus paclitaxel plus trastuzumab followed by FEC-75 plus trastuzumab as neoadjuvant treatment for patients with HER2-positive breast cancer (Z1041): a randomised, controlled, phase 3 trial.	The Lancet. Oncology	2013	35
14643116	2147	Olsson SB	Stroke prevention with the oral direct thrombin inhibitor ximelagatran compared with warfarin in patients with non-valvular atrial fibrillation (SPORTIF III): randomised controlled trial.	Lancet	2003	86
15701910	2147	Albers GW	Ximelagatran vs warfarin for stroke prevention in patients with nonvalvular atrial fibrillation: a randomized trial.	JAMA	2005	74
18399711	2147	Stangier J	Clinical pharmacokinetics and pharmacodynamics of the oral direct thrombin inhibitor dabigatran etexilate.	Clinical pharmacokinetics	2008	95
18499566	2147	Stone GW	Bivalirudin during primary PCI in acute myocardial infarction.	The New England journal of medicine	2008	162
19696042	2147	Stangier J	Pharmacology, pharmacokinetics, and pharmacodynamics of dabigatran etexilate, an oral direct thrombin inhibitor.	Clinical and applied thrombosis/hemostasis 	2009	50
19717844	2147	Connolly SJ	Dabigatran versus warfarin in patients with atrial fibrillation.	The New England journal of medicine	2009	1195
21551462	2147	Oldgren J	Dabigatran vs. placebo in patients with acute coronary syndromes on dual antiplatelet therapy: a randomized, double-blind, phase II trial.	European heart journal	2011	59
22037947	2147	Davalos D	Fibrinogen as a key regulator of inflammation in disease.	Seminars in immunopathology	2012	104
22077816	2147	Tricoci P	Thrombin-receptor antagonist vorapaxar in acute coronary syndromes.	The New England journal of medicine	2012	106
22443427	2147	Morrow DA	Vorapaxar in the secondary prevention of atherothrombotic events.	The New England journal of medicine	2012	117
22497820	2147	De Caterina R	New oral anticoagulants in atrial fibrillation and acute coronary syndromes: ESC Working Group on Thrombosis-Task Force on Anticoagulants in Heart Disease position paper.	Journal of the American College of Cardiology	2012	42
23562920	2147	Larsen TB	Efficacy and safety of dabigatran etexilate and warfarin in "real-world" patients with atrial fibrillation: a prospective nationwide cohort study.	Journal of the American College of Cardiology	2013	66
23991661	2147	Eikelboom JW	Dabigatran versus warfarin in patients with mechanical heart valves.	The New England journal of medicine	2013	90
24226379	2147	De Caterina R	Vitamin K antagonists in heart disease: current status and perspectives (Section III). Position paper of the ESC Working Group on Thrombosis--Task Force on Anticoagulants in Heart Disease.	Thrombosis and haemostasis	2013	36
17110453	2149	Mosnier LO	The cytoprotective protein C pathway.	Blood	2007	231
18574281	2159	Monagle P	Antithrombotic therapy in neonates and children: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).	Chest	2008	83
19470889	2159	APPRAISE Steering Committee and Investigators.	Apixaban, an oral, direct, selective factor Xa inhibitor, in combination with antiplatelet therapy after acute coronary syndrome: results of the Apixaban for Prevention of Acute Ischemic and Safety Events (APPRAISE) trial.	Circulation	2009	54
19539361	2159	Mega JL	Rivaroxaban versus placebo in patients with acute coronary syndromes (ATLAS ACS-TIMI 46): a randomised, double-blind, phase II trial.	Lancet	2009	65
20211293	2159	ROCKET AF Study Investigators.	Rivaroxaban-once daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation: rationale and design of the ROCKET AF study.	American heart journal	2010	66
20694273	2159	Weitz JI	Randomised, parallel-group, multicentre, multinational phase 2 study comparing edoxaban, an oral factor Xa inhibitor, with warfarin for stroke prevention in patients with atrial fibrillation.	Thrombosis and haemostasis	2010	52
20934556	2159	Ruff CT	Evaluation of the novel factor Xa inhibitor edoxaban compared with warfarin in patients with atrial fibrillation: design and rationale for the Effective aNticoaGulation with factor xA next GEneration in Atrial Fibrillation-Thrombolysis In Myocardial Infarction study 48 (ENGAGE AF-TIMI 48).	American heart journal	2010	60
21870978	2159	Granger CB	Apixaban versus warfarin in patients with atrial fibrillation.	The New England journal of medicine	2011	865
21873708	2159	Fox KA	Prevention of stroke and systemic embolism with rivaroxaban compared with warfarin in patients with non-valvular atrial fibrillation and moderate renal impairment.	European heart journal	2011	72
21895039	2159	Mueck W	Rivaroxaban: population pharmacokinetic analyses in patients treated for acute deep-vein thrombosis and exposure simulations in patients with atrial fibrillation treated for stroke prevention.	Clinical pharmacokinetics	2011	48
22433576	2159	Skanes AC	Focused 2012 update of the Canadian Cardiovascular Society atrial fibrillation guidelines: recommendations for stroke prevention and rate/rhythm control.	The Canadian journal of cardiology	2012	77
23212720	2159	Piccini JP	Renal dysfunction as a predictor of stroke and systemic embolism in patients with nonvalvular atrial fibrillation: validation of the R(2)CHADS(2) index in the ROCKET AF (Rivaroxaban Once-daily, oral, direct factor Xa inhibition Compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation) and ATRIA (AnTicoagulation and Risk factors In Atrial fibrillation) study cohorts.	Circulation	2013	63
23216615	2159	Agnelli G	Apixaban for extended treatment of venous thromboembolism.	The New England journal of medicine	2013	115
23391196	2159	Patel MR	Outcomes of discontinuing rivaroxaban compared with warfarin in patients with nonvalvular atrial fibrillation: analysis from the ROCKET AF trial (Rivaroxaban Once-Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation).	Journal of the American College of Cardiology	2013	36
23451769	2159	Frost C	Safety, pharmacokinetics and pharmacodynamics of multiple oral doses of apixaban, a factor Xa inhibitor, in healthy subjects.	British journal of clinical pharmacology	2013	40
23784266	2159	Mendell J	Drug-drug interaction studies of cardiovascular drugs involving P-glycoprotein, an efflux transporter, on the pharmacokinetics of edoxaban, an oral factor Xa inhibitor.	American journal of cardiovascular drugs 	2013	34
23808982	2159	Agnelli G	Oral apixaban for the treatment of acute venous thromboembolism.	The New England journal of medicine	2013	187
24211508	2159	Flaker G	Efficacy and safety of apixaban in patients after cardioversion for atrial fibrillation: insights from the ARISTOTLE Trial (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation).	Journal of the American College of Cardiology	2014	30
24251359	2159	Giugliano RP	Edoxaban versus warfarin in patients with atrial fibrillation.	The New England journal of medicine	2013	404
24353282	2159	Azoulay L	Initiation of warfarin in patients with atrial fibrillation: early effects on ischaemic strokes.	European heart journal	2014	22
24552831	2159	Sherwood MW	Outcomes of temporary interruption of rivaroxaban compared with warfarin in patients with nonvalvular atrial fibrillation: results from the rivaroxaban once daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation (ROCKET AF).	Circulation	2014	34
24895454	2159	Halperin JL	Efficacy and safety of rivaroxaban compared with warfarin among elderly patients with nonvalvular atrial fibrillation in the Rivaroxaban Once Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF).	Circulation	2014	41
25403645	2159	Zahir H	Edoxaban effects on bleeding following punch biopsy and reversal by a 4-factor prothrombin complex concentrate.	Circulation	2015	28
25769361	2159	Ruff CT	Association between edoxaban dose, concentration, anti-Factor Xa activity, and outcomes: an analysis of data from the randomised, double-blind ENGAGE AF-TIMI 48 trial.	Lancet	2015	24
26330425	2159	Camm AJ	XANTUS: a real-world, prospective, observational study of patients treated with rivaroxaban for stroke prevention in atrial fibrillation.	European heart journal	2016	40
8035924	2244	Breteler MM	Cerebral white matter lesions, vascular risk factors, and cognitive function in a population-based study: the Rotterdam Study.	Neurology	1994	148
8353913	2244	Newman AB	Ankle-arm index as a marker of atherosclerosis in the Cardiovascular Health Study. Cardiovascular Heart Study (CHS) Collaborative Research Group.	Circulation	1993	162
10187889	2244	Ebrahim S	Carotid plaque, intima media thickness, cardiovascular risk factors, and prevalent cardiovascular disease in men and women: the British Regional Heart Study.	Stroke	1999	107
10862640	2244	Guérin AP	Arterial stiffening and vascular calcifications in end-stage renal disease.	Nephrology, dialysis, transplantation 	2000	100
23194937	2244	Guo Y	Inflammation in atrial fibrillation.	Journal of the American College of Cardiology	2012	83
23755138	2244	Menzaghi C	Serum resistin, cardiovascular disease and all-cause mortality in patients with type 2 diabetes.	PloS one	2014	24
16697959	2247	Lee J	Tumor stem cells derived from glioblastomas cultured in bFGF and EGF more closely mirror the phenotype and genotype of primary tumors than do serum-cultured cell lines.	Cancer cell	2006	734
14981009	2641	Nikolaidis LA	Effects of glucagon-like peptide-1 in patients with acute myocardial infarction and left ventricular dysfunction after successful reperfusion.	Circulation	2004	186
17174230	2641	Sokos GG	Glucagon-like peptide-1 infusion improves left ventricular ejection fraction and functional status in patients with chronic heart failure.	Journal of cardiac failure	2006	134
20929995	2641	Best JH	Risk of cardiovascular disease events in patients with type 2 diabetes prescribed the glucagon-like peptide 1 (GLP-1) receptor agonist exenatide twice daily or other glucose-lowering therapies: a retrospective analysis of the LifeLink database.	Diabetes care	2011	57
27295427	2641	Marso SP	Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes.	The New England journal of medicine	2016	305
27633186	2641	Marso SP	Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes.	The New England journal of medicine	2016	174
15280535	2670	Kelly S	Transplanted human fetal neural stem cells survive, migrate, and differentiate in ischemic rat cerebral cortex.	Proceedings of the National Academy of Sciences of the United States of America	2004	163
17405762	2670	Misu T	Loss of aquaporin 4 in lesions of neuromyelitis optica: distinction from multiple sclerosis.	Brain 	2007	125
23769173	2670	Yuan T	Human induced pluripotent stem cell-derived neural stem cells survive, migrate, differentiate, and improve neurologic function in a rat model of middle cerebral artery occlusion.	Stem cell research and therapy	2013	31
18256394	2688	Merideth MA	Phenotype and course of Hutchinson-Gilford progeria syndrome.	The New England journal of medicine	2008	160
11386930	2717	Schiffmann R	Enzyme replacement therapy in Fabry disease: a randomized controlled trial.	JAMA	2001	161
23868944	2740	Woo JS	Cardioprotective effects of exenatide in patients with ST-segment-elevation myocardial infarction undergoing primary percutaneous coronary intervention: results of exenatide myocardial protection in revascularization study.	Arteriosclerosis, thrombosis, and vascular biology	2013	35
23999914	2740	Hölscher C	Central effects of GLP-1: new opportunities for treatments of neurodegenerative diseases.	The Journal of endocrinology	2014	37
26630143	2740	Pfeffer MA	Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome.	The New England journal of medicine	2015	149
16935624	3383	Huang J	Inflammation in stroke and focal cerebral ischemia.	Surgical neurology	2006	146
16402109	3552	Lucas SM	The role of inflammation in CNS injury and disease.	British journal of pharmacology	2006	249
17088043	3552	Dantzer R	Twenty years of research on cytokine-induced sickness behavior.	Brain, behavior, and immunity	2007	286
17956293	3552	Simi A	Interleukin-1 and inflammatory neurodegeneration.	Biochemical Society transactions	2007	64
22739623	3552	Lambertsen KL	Inflammatory cytokines in experimental and human stroke.	Journal of cerebral blood flow and metabolism 	2012	126
25726324	3552	Interleukin 1 Genetics Consortium.	Cardiometabolic effects of genetic upregulation of the interleukin 1 receptor antagonist: a Mendelian randomisation analysis.	The lancet. Diabetes and endocrinology	2015	21
8910831	3553	Beck J	Periodontal disease and cardiovascular disease.	Journal of periodontology	1996	187
22219513	3553	Csiszar A	Age-associated proinflammatory secretory phenotype in vascular smooth muscle cells from the non-human primate Macaca mulatta: reversal by resveratrol treatment.	The journals of gerontology. Series A, Biological sciences and medical sciences	2012	42
11022058	3569	Vila N	Proinflammatory cytokines and early neurological worsening in ischemic stroke.	Stroke	2000	111
11388092	3569	Pinede L	Clinical presentation of left atrial cardiac myxoma. A series of 112 consecutive cases.	Medicine	2001	102
18156155	3569	Lee ST	Anti-inflammatory mechanism of intravascular neural stem cell transplantation in haemorrhagic stroke.	Brain 	2008	120
18753925	3569	Strategies for Management of Anti-Retroviral Therapy/INSIGHT.	Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients.	AIDS	2008	86
19018268	3569	Suzuki S	Ambivalent aspects of interleukin-6 in cerebral ischemia: inflammatory versus neurotrophic aspects.	Journal of cerebral blood flow and metabolism 	2009	60
22421340	3569	Interleukin-6 Receptor Mendelian Randomisation Analysis (IL6R MR) Consortium.	The interleukin-6 receptor as a target for prevention of coronary heart disease: a mendelian randomisation analysis.	Lancet	2012	156
23178647	3569	Fülster S	Muscle wasting in patients with chronic heart failure: results from the studies investigating co-morbidities aggravating heart failure (SICA-HF).	European heart journal	2013	44
23340215	3569	Singh AK	Metabolic syndrome and chronic kidney disease.	Current opinion in nephrology and hypertension	2013	28
24795473	3569	Tenorio AR	Soluble markers of inflammation and coagulation but not T-cell activation predict non-AIDS-defining morbid events during suppressive antiretroviral treatment.	The Journal of infectious diseases	2014	128
7839388	3630	Sacco RL	Race-ethnicity and determinants of intracranial atherosclerotic cerebral infarction. The Northern Manhattan Stroke Study.	Stroke	1995	152
10788730	3630	Block G	A rapid food screener to assess fat and fruit and vegetable intake.	American journal of preventive medicine	2000	114
12087016	3630	Hanley AJ	Homeostasis model assessment of insulin resistance in relation to the incidence of cardiovascular disease: the San Antonio Heart Study.	Diabetes care	2002	103
15477536	3630	Luchsinger JA	Hyperinsulinemia and risk of Alzheimer disease.	Neurology	2004	149
16061606	3630	Hannon TS	Childhood obesity and type 2 diabetes mellitus.	Pediatrics	2005	73
16361024	3630	Biessels GJ	Risk of dementia in diabetes mellitus: a systematic review.	The Lancet. Neurology	2006	339
16801565	3630	Knopp RH	Efficacy and safety of atorvastatin in the prevention of cardiovascular end points in subjects with type 2 diabetes: the Atorvastatin Study for Prevention of Coronary Heart Disease Endpoints in non-insulin-dependent diabetes mellitus (ASPEN).	Diabetes care	2006	74
16848698	3630	Cahill GF Jr	Fuel metabolism in starvation.	Annual review of nutrition	2006	154
17707755	3630	Messerli FH	Essential hypertension.	Lancet	2007	82
18673007	3630	King GL	The role of inflammatory cytokines in diabetes and its complications.	Journal of periodontology	2008	98
18801863	3630	Cade WT	Diabetes-related microvascular and macrovascular diseases in the physical therapy setting.	Physical therapy	2008	82
20228402	3630	NAVIGATOR Study Group.	Effect of nateglinide on the incidence of diabetes and cardiovascular events.	The New England journal of medicine	2010	83
21109513	3630	Kitas GD	Cardiovascular disease in rheumatoid arthritis: state of the art and future perspectives.	Annals of the rheumatic diseases	2011	57
21466619	3630	Long AN	Comorbidities of diabetes and hypertension: mechanisms and approach to target organ protection.	Journal of clinical hypertension	2011	52
21471135	3630	Schramm TK	Mortality and cardiovascular risk associated with different insulin secretagogues compared with metformin in type 2 diabetes, with or without a previous myocardial infarction: a nationwide study.	European heart journal	2011	67
21472114	3630	Canani RB	Potential beneficial effects of butyrate in intestinal and extraintestinal diseases.	World journal of gastroenterology	2011	117
24250251	3630	Rajendran P	The vascular endothelium and human diseases.	International journal of biological sciences	2013	90
24663222	3630	Laakso M	Insulin resistance and hyperglycaemia in cardiovascular disease development.	Nature reviews. Endocrinology	2014	44
26319013	3630	Negro F	Extrahepatic morbidity and mortality of chronic hepatitis C.	Gastroenterology	2015	33
26886418	3630	Kernan WN	Pioglitazone after Ischemic Stroke or Transient Ischemic Attack.	The New England journal of medicine	2016	89
21251183	3645	Petoumenos K	Rates of cardiovascular disease following smoking cessation in patients with HIV infection: results from the D:A:D study(*).	HIV medicine	2011	50
21416498	3645	Howard VJ	Disparities in stroke incidence contributing to disparities in stroke mortality.	Annals of neurology	2011	123
25027141	3645	Koton S	Stroke incidence and mortality trends in US communities, 1987 to 2011.	JAMA	2014	62
15927972	3791	Schmidt-Lucke C	Reduced number of circulating endothelial progenitor cells predicts future cardiovascular events: proof of concept for the clinical importance of endogenous vascular repair.	Circulation	2005	216
18063830	3791	Yip HK	Level and value of circulating endothelial progenitor cells in patients after acute ischemic stroke.	Stroke	2008	59
22553043	3934	Zamanian JL	Genomic analysis of reactive astrogliosis.	The Journal of neuroscience 	2012	278
25311702	3934	Liu KD	Urine neutrophil gelatinase-associated lipocalin and risk of cardiovascular disease and death in CKD: results from the Chronic Renal Insufficiency Cohort (CRIC) Study.	American journal of kidney diseases 	2015	18
22939561	3958	Ho JE	Galectin-3, a marker of cardiac fibrosis, predicts incident heart failure in the community.	Journal of the American College of Cardiology	2012	86
23349535	4306	Bender SB	Mineralocorticoid receptor-mediated vascular insulin resistance: an early contributor to diabetes-related vascular disease?	Diabetes	2013	44
24716680	4306	Pitt B	Spironolactone for heart failure with preserved ejection fraction.	The New England journal of medicine	2014	156
25176015	4311	McMurray JJ	Angiotensin-neprilysin inhibition versus enalapril in heart failure.	The New England journal of medicine	2014	266
25403646	4311	Packer M	Angiotensin receptor neprilysin inhibition compared with enalapril on the risk of clinical progression in surviving patients with heart failure.	Circulation	2015	59
12566373	4313	Montaner J	Matrix metalloproteinase-9 pretreatment level predicts intracranial hemorrhagic complications after thrombolysis in human stroke.	Circulation	2003	94
21454822	4313	Candelario-Jalil E	Matrix metalloproteinases are associated with increased blood-brain barrier opening in vascular cognitive impairment.	Stroke	2011	47
24281743	4313	Jickling GC	Hemorrhagic transformation after ischemic stroke in animals and humans.	Journal of cerebral blood flow and metabolism 	2014	56
16690896	4318	Rosell A	Increased brain expression of matrix metalloproteinase-9 after ischemic and hemorrhagic human stroke.	Stroke	2006	107
18323498	4318	Rosell A	MMP-9-positive neutrophil infiltration is associated to blood-brain barrier breakdown and basal lamina type IV collagen degradation during hemorrhagic transformation after human ischemic stroke.	Stroke	2008	102
20035078	4318	Barr TL	Blood-brain barrier disruption in humans is independently associated with increased matrix metalloproteinase-9.	Stroke	2010	49
21044610	4318	Ramos-Fernandez M	Matrix metalloproteinase-9 as a marker for acute ischemic stroke: a systematic review.	Journal of stroke and cerebrovascular diseases 	2011	45
15713945	4513	Nussmeier NA	Complications of the COX-2 inhibitors parecoxib and valdecoxib after cardiac surgery.	The New England journal of medicine	2005	124
20059330	4513	Grosser T	Emotion recollected in tranquility: lessons learned from the COX-2 saga.	Annual review of medicine	2010	62
23726390	4513	Coxib and traditional NSAID Trialists' (CNT) Collaboration.	Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials.	Lancet	2013	164
15652605	4524	Casas JP	Homocysteine and stroke: evidence on a causal link from mendelian randomisation.	Lancet	2005	77
20385928	4524	Kenet G	Impact of thrombophilia on risk of arterial ischemic stroke or cerebral sinovenous thrombosis in neonates and children: a systematic review and meta-analysis of observational studies.	Circulation	2010	42
25771069	4524	Huo Y	Efficacy of folic acid therapy in primary prevention of stroke among adults with hypertension in China: the CSPPT randomized clinical trial.	JAMA	2015	88
17848650	4709	Jamison RL	Effect of homocysteine lowering on mortality and vascular disease in advanced chronic kidney disease and end-stage renal disease: a randomized controlled trial.	JAMA	2007	97
20571015	4709	Study of the Effectiveness of Additional Reductions in Cholesterol and Homocysteine (SEARCH) Collaborative Group.	Effects of homocysteine-lowering with folic acid plus vitamin B12 vs placebo on mortality and major morbidity in myocardial infarction survivors: a randomized trial.	JAMA	2010	61
8878478	4854	Joutel A	Notch3 mutations in CADASIL, a hereditary adult-onset condition causing stroke and dementia.	Nature	1996	302
19164813	4854	Gaengel K	Endothelial-mural cell signaling in vascular development and angiogenesis.	Arteriosclerosis, thrombosis, and vascular biology	2009	217
19539236	4854	Chabriat H	Cadasil.	The Lancet. Neurology	2009	141
15716560	4879	Kragelund C	N-terminal pro-B-type natriuretic peptide and long-term mortality in stable coronary heart disease.	The New England journal of medicine	2005	82
17090767	4879	Bursi F	Systolic and diastolic heart failure in the community.	JAMA	2006	185
18154959	4879	Daniels LB	Natriuretic peptides.	Journal of the American College of Cardiology	2007	143
19176440	4879	Pfisterer M	BNP-guided vs symptom-guided heart failure therapy: the Trial of Intensified vs Standard Medical Therapy in Elderly Patients With Congestive Heart Failure (TIME-CHF) randomized trial.	JAMA	2009	65
23040568	4879	Akiyama E	Incremental prognostic significance of peripheral endothelial dysfunction in patients with heart failure with normal left ventricular ejection fraction.	Journal of the American College of Cardiology	2012	39
23500300	4879	van Veldhuisen DJ	B-type natriuretic peptide and prognosis in heart failure patients with preserved and reduced ejection fraction.	Journal of the American College of Cardiology	2013	64
23821090	4879	Ledwidge M	Natriuretic peptide-based screening and collaborative care for heart failure: the STOP-HF randomized trial.	JAMA	2013	48
24275629	4879	Matsuzawa Y	Peripheral endothelial function and cardiovascular events in high-risk patients.	Journal of the American Heart Association	2013	33
26056125	4879	Chung ES	Changes in ventricular remodelling and clinical status during the year following a single administration of stromal cell-derived factor-1 non-viral gene therapy in chronic ischaemic heart failure patients: the STOP-HF randomized Phase II trial.	European heart journal	2015	25
17261678	5187	Hirtz D	How common are the "common" neurologic disorders?	Neurology	2007	240
18584872	5187	Wong TY	Prevalence and risk factors for diabetic retinopathy: the Singapore Malay Eye Study.	Ophthalmology	2008	72
20576628	5187	Wijndaele K	Television viewing time independently predicts all-cause and cardiovascular mortality: the EPIC Norfolk study.	International journal of epidemiology	2011	79
25862803	5187	Sico JJ	HIV status and the risk of ischemic stroke among men.	Neurology	2015	34
9368550	5327	-	Intracerebral hemorrhage after intravenous t-PA therapy for ischemic stroke. The NINDS t-PA Stroke Study Group.	Stroke	1997	124
10591382	5327	Furlan A	Intra-arterial prourokinase for acute ischemic stroke. The PROACT II study: a randomized controlled trial. Prolyse in Acute Cerebral Thromboembolism.	JAMA	1999	291
10591384	5327	Clark WM	Recombinant tissue-type plasminogen activator (Alteplase) for ischemic stroke 3 to 5 hours after symptom onset. The ATLANTIS Study: a randomized controlled trial. Alteplase Thrombolysis for Acute Noninterventional Therapy in Ischemic Stroke.	JAMA	1999	103
15548777	5327	Alexandrov AV	Ultrasound-enhanced systemic thrombolysis for acute ischemic stroke.	The New England journal of medicine	2004	145
17521716	5327	Durukan A	Acute ischemic stroke: overview of major experimental rodent models, pathophysiology, and therapy of focal cerebral ischemia.	Pharmacology, biochemistry, and behavior	2007	155
18963068	5327	Yepes M	Tissue-type plasminogen activator in the ischemic brain: more than a thrombolytic.	Trends in neurosciences	2009	73
21311083	5327	Fonarow GC	Timeliness of tissue-type plasminogen activator therapy in acute ischemic stroke: patient characteristics, hospital factors, and outcomes associated with door-to-needle times within 60 minutes.	Circulation	2011	100
21885841	5327	Fonarow GC	Improving door-to-needle times in acute ischemic stroke: the design and rationale for the American Heart Association/American Stroke Association's Target: Stroke initiative.	Stroke	2011	51
23387822	5327	Ciccone A	Endovascular treatment for acute ischemic stroke.	The New England journal of medicine	2013	188
23390923	5327	Broderick JP	Endovascular therapy after intravenous t-PA versus t-PA alone for stroke.	The New England journal of medicine	2013	317
23391763	5327	Mould WA	Minimally invasive surgery plus recombinant tissue-type plasminogen activator for intracerebral hemorrhage evacuation decreases perihematomal edema.	Stroke	2013	34
23780461	5327	Saver JL	Time to treatment with intravenous tissue plasminogen activator and outcome from acute ischemic stroke.	JAMA	2013	97
24046398	5327	Schwamm LH	Temporal trends in patient characteristics and treatment with intravenous thrombolysis among acute ischemic stroke patients at Get With The Guidelines-Stroke hospitals.	Circulation. Cardiovascular quality and outcomes	2013	44
24335227	5327	Hill MD	Alberta Stroke Program early computed tomography score to select patients for endovascular treatment: Interventional Management of Stroke (IMS)-III Trial.	Stroke	2014	24
25882376	5327	Saver JL	Stent-retriever thrombectomy after intravenous t-PA vs. t-PA alone in stroke.	The New England journal of medicine	2015	362
18349088	5444	Bhattacharyya T	Relationship of paraoxonase 1 (PON1) gene polymorphisms and functional activity with systemic oxidative stress and cardiovascular risk.	JAMA	2008	129
16214598	5468	Dormandy JA	Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial.	Lancet	2005	553
19782001	5580	Pendlebury ST	Prevalence, incidence, and factors associated with pre-stroke and post-stroke dementia: a systematic review and meta-analysis.	The Lancet. Neurology	2009	187
21778438	5580	Gorelick PB	Vascular contributions to cognitive impairment and dementia: a statement for healthcare professionals from the american heart association/american stroke association.	Stroke	2011	606
22556195	5580	Connolly ES Jr	Guidelines for the management of aneurysmal subarachnoid hemorrhage: a guideline for healthcare professionals from the American Heart Association/american Stroke Association.	Stroke	2012	231
10557349	5743	Yrjänheikki J	A tetracycline derivative, minocycline, reduces inflammation and protects against focal cerebral ischemia with a wide therapeutic window.	Proceedings of the National Academy of Sciences of the United States of America	1999	227
11509060	5743	Mukherjee D	Risk of cardiovascular events associated with selective COX-2 inhibitors.	JAMA	2001	209
15713944	5743	Solomon SD	Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention.	The New England journal of medicine	2005	354
18378608	5743	Solomon SD	Cardiovascular risk of celecoxib in 6 randomized placebo-controlled trials: the cross trial safety analysis.	Circulation	2008	93
20007921	5743	Albini A	Cardiotoxicity of anticancer drugs: the need for cardio-oncology and cardio-oncological prevention.	Journal of the National Cancer Institute	2010	108
25322082	5743	Köhler O	Effect of anti-inflammatory treatment on depression, depressive symptoms, and adverse effects: a systematic review and meta-analysis of randomized clinical trials.	JAMA psychiatry	2014	80
25776112	5743	Solomon DH	Disease activity in rheumatoid arthritis and the risk of cardiovascular events.	Arthritis and rheumatology	2015	28
18082509	5817	Hunter KS	Pulmonary vascular input impedance is a combined measure of pulmonary vascular resistance and stiffness and predicts clinical outcomes better than pulmonary vascular resistance alone in pediatric patients with pulmonary hypertension.	American heart journal	2008	59
22133851	5817	van de Veerdonk MC	Progressive right ventricular dysfunction in patients with pulmonary arterial hypertension responding to therapy.	Journal of the American College of Cardiology	2011	123
6382011	5972	Cohn JN	Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure.	The New England journal of medicine	1984	309
15837256	5972	Milliez P	Evidence for an increased rate of cardiovascular events in patients with primary aldosteronism.	Journal of the American College of Cardiology	2005	163
19289633	5972	Böger RH	Plasma asymmetric dimethylarginine and incidence of cardiovascular disease and death in the community.	Circulation	2009	68
19874988	5972	Triposkiadis F	The sympathetic nervous system in heart failure physiology, pathophysiology, and clinical implications.	Journal of the American College of Cardiology	2009	138
23121378	5972	Parving HH	Cardiorenal end points in a trial of aliskiren for type 2 diabetes.	The New England journal of medicine	2012	165
23478743	5972	Gheorghiade M	Effect of aliskiren on postdischarge mortality and heart failure readmissions among patients hospitalized for heart failure: the ASTRONAUT randomized trial.	JAMA	2013	40
7733127	6240	Krahn AD	The natural history of atrial fibrillation: incidence, risk factors, and prognosis in the Manitoba Follow-Up Study.	The American journal of medicine	1995	221
16620828	6240	Heald CL	Risk of mortality and cardiovascular disease associated with the ankle-brachial index: Systematic review.	Atherosclerosis	2006	80
20191515	6240	Kim SY	Hyperuricemia and coronary heart disease: a systematic review and meta-analysis.	Arthritis care and research	2010	115
22537354	6240	Miller CS	Meta-analysis of efficacy and safety of new oral anticoagulants (dabigatran, rivaroxaban, apixaban) versus warfarin in patients with atrial fibrillation.	The American journal of cardiology	2012	70
26324537	6240	Udell JA	Long-term dual antiplatelet therapy for secondary prevention of cardiovascular events in the subgroup of patients with previous myocardial infarction: a collaborative meta-analysis of randomized trials.	European heart journal	2016	27
26378978	6524	Zinman B	Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes.	The New England journal of medicine	2015	531
27009625	6524	Wu JH	Effects of sodium-glucose cotransporter-2 inhibitors on cardiovascular events, death, and major safety outcomes in adults with type 2 diabetes: a systematic review and meta-analysis.	The lancet. Diabetes and endocrinology	2016	52
27208375	6524	Abdul-Ghani M	SGLT2 Inhibitors and Cardiovascular Risk: Lessons Learned From the EMPA-REG OUTCOME Study.	Diabetes care	2016	33
27470878	6524	Heerspink HJ	Sodium Glucose Cotransporter 2 Inhibitors in the Treatment of Diabetes Mellitus: Cardiovascular and Kidney Effects, Potential Mechanisms, and Clinical Applications.	Circulation	2016	42
17485581	7124	Maybaum S	Cardiac improvement during mechanical circulatory support: a prospective multicenter study of the LVAD Working Group.	Circulation	2007	65
18325087	7124	Naranjo A	Cardiovascular disease in patients with rheumatoid arthritis: results from the QUEST-RA study.	Arthritis research and therapy	2008	61
21109516	7124	Greenberg JD	Tumour necrosis factor antagonist use and associated risk reduction of cardiovascular events among patients with rheumatoid arthritis.	Annals of the rheumatic diseases	2011	58
25422582	7124	Tuttolomondo A	Studies of selective TNF inhibitors in the treatment of brain injury from stroke and trauma: a review of the evidence to date.	Drug design, development and therapy	2014	32
19188504	7137	Hoole SP	Cardiac Remote Ischemic Preconditioning in Coronary Stenting (CRISP Stent) Study: a prospective, randomized control trial.	Circulation	2009	94
24829362	7137	Chin CW	High-sensitivity troponin I concentrations are a marker of an advanced hypertrophic response and adverse outcomes in patients with aortic stenosis.	European heart journal	2014	34
21422391	7139	Saunders JT	Cardiac troponin T measured by a highly sensitive assay predicts coronary heart disease, heart failure, and mortality in the Atherosclerosis Risk in Communities Study.	Circulation	2011	152
26362631	7276	Fontana M	Prognostic Value of Late Gadolinium Enhancement Cardiovascular Magnetic Resonance in Cardiac Amyloidosis.	Circulation	2015	38
14557356	7422	Britten MB	Infarct remodeling after intracoronary progenitor cell treatment in patients with acute myocardial infarction (TOPCARE-AMI): mechanistic insights from serial contrast-enhanced magnetic resonance imaging.	Circulation	2003	89
20156114	7422	Ranpura V	Risk of cardiac ischemia and arterial thromboembolic events with the angiogenesis inhibitor bevacizumab in cancer patients: a meta-analysis of randomized controlled trials.	Acta oncologica	2010	47
21732485	7422	Horie N	Transplanted stem cell-secreted vascular endothelial growth factor effects poststroke recovery, inflammation, and vascular repair.	Stem cells	2011	73
22495829	7422	Oki K	Human-induced pluripotent stem cells form functional neurons and improve recovery after grafting in stroke-damaged brain.	Stem cells	2012	70
16931783	7450	Ohira T	Risk factors for ischemic stroke subtypes: the Atherosclerosis Risk in Communities study.	Stroke	2006	77
19246701	7450	Kearney-Schwartz A	Vascular structure and function is correlated to cognitive performance and white matter hyperintensities in older hypertensive patients with subjective memory complaints.	Stroke	2009	55
20435228	7941	Lp-PLA(2) Studies Collaboration.	Lipoprotein-associated phospholipase A(2) and risk of coronary disease, stroke, and mortality: collaborative analysis of 32 prospective studies.	Lancet	2010	147
24678955	7941	STABILITY Investigators.	Darapladib for preventing ischemic events in stable coronary heart disease.	The New England journal of medicine	2014	82
25173516	7941	O'Donoghue ML	Effect of darapladib on major coronary events after an acute coronary syndrome: the SOLID-TIMI 52 randomized clinical trial.	JAMA	2014	60
20525642	8074	Seiler S	FGF-23 and future cardiovascular events in patients with chronic kidney disease before initiation of dialysis treatment.	Nephrology, dialysis, transplantation 	2010	55
24158986	8074	Scialla JJ	Fibroblast growth factor-23 and cardiovascular events in CKD.	Journal of the American Society of Nephrology 	2014	87
23418004	9337	Becske T	Pipeline for uncoilable or failed aneurysms: results from a multicenter clinical trial.	Radiology	2013	70
24417951	9370	Kishida K	Adiponectin as a routine clinical biomarker.	Best practice and research. Clinical endocrinology and metabolism	2014	31
23546563	9933	Mozaffarian D	Plasma phospholipid long-chain ω-3 fatty acids and total and cause-specific mortality in older adults: a cohort study.	Annals of internal medicine	2013	47
24351702	9933	de Oliveira Otto MC	Circulating and dietary omega-3 and omega-6 polyunsaturated fatty acids and incidence of CVD in the Multi-Ethnic Study of Atherosclerosis.	Journal of the American Heart Association	2013	33
26068959	9933	Hooper L	Reduction in saturated fat intake for cardiovascular disease.	The Cochrane database of systematic reviews	2015	41
25440796	22796	Schwartz GG	Effect of alirocumab, a monoclonal antibody to PCSK9, on long-term cardiovascular outcomes following acute coronary syndromes: rationale and design of the ODYSSEY outcomes trial.	American heart journal	2014	44
21045078	26284	Farag YM	Diabesity: an overview of a rising epidemic.	Nephrology, dialysis, transplantation 	2011	51
22653528	26284	Holt JL	Neuroimaging studies of the aging HIV-1-infected brain.	Journal of neurovirology	2012	44
22077192	51703	Mega JL	Rivaroxaban in patients with a recent acute coronary syndrome.	The New England journal of medicine	2012	186
20561675	55016	O'Donnell MJ	Risk factors for ischaemic and intracerebral haemorrhagic stroke in 22 countries (the INTERSTROKE study): a case-control study.	Lancet	2010	451
22377813	57674	Miyatake S	Homozygous c.14576G&amp;gt;A variant of RNF213 predicts early-onset and severe form of moyamoya disease.	Neurology	2012	38
19717846	64805	Wallentin L	Ticagrelor versus clopidogrel in patients with acute coronary syndromes.	The New England journal of medicine	2009	530
20079528	64805	Cannon CP	Comparison of ticagrelor with clopidogrel in patients with a planned invasive strategy for acute coronary syndromes (PLATO): a randomised double-blind study.	Lancet	2010	61
20179285	64805	Breet NJ	Comparison of platelet function tests in predicting clinical outcome in patients undergoing coronary stent implantation.	JAMA	2010	91
23121439	64805	Collet JP	Bedside monitoring to adjust antiplatelet therapy for coronary stenting.	The New England journal of medicine	2012	82
24670650	64805	Zhang K	Structure of the human P2Y12 receptor in complex with an antithrombotic drug.	Nature	2014	69
25773268	64805	Bonaca MP	Long-term use of ticagrelor in patients with prior myocardial infarction.	The New England journal of medicine	2015	89
25773378	255738	Robinson JG	Efficacy and safety of alirocumab in reducing lipids and cardiovascular events.	The New England journal of medicine	2015	224
25773607	255738	Sabatine MS	Efficacy and safety of evolocumab in reducing lipids and cardiovascular events.	The New England journal of medicine	2015	191
26920601	255738	Sabatine MS	Rationale and design of the Further cardiovascular OUtcomes Research with PCSK9 Inhibition in subjects with Elevated Risk trial.	American heart journal	2016	25
20233780	286205	Hiratzka LF	2010 ACCF/AHA/AATS/ACR/ASA/SCA/SCAI/SIR/STS/SVM guidelines for the diagnosis and management of patients with Thoracic Aortic Disease: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, American Association for Thoracic Surgery, American College of Radiology, American Stroke Association, Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, Society of Interventional Radiology, Society of Thoracic Surgeons, and Society for Vascular Medicine.	Circulation	2010	246
20359588	286205	Hiratzka LF	2010 ACCF/AHA/AATS/ACR/ASA/SCA/SCAI/SIR/STS/SVM Guidelines for the diagnosis and management of patients with thoracic aortic disease. A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, American Association for Thoracic Surgery, American College of Radiology,American Stroke Association, Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, Society of Interventional Radiology, Society of Thoracic Surgeons,and Society for Vascular Medicine.	Journal of the American College of Cardiology	2010	146
